Merck KGaA: aims to return to organic growth in 2024

(CercleFinance.com) - Group net sales fell by 5.
6% to E20,993m in 2023 (-1.6% in organic terms).

EBITDA fell by 14.2% to E5,879m (-9.0% in organic terms).

Healthcare's excellent sales and earnings performance demonstrates the benefits of Merck's diversified business model.

EPS amounted to E8.49. On this basis, management will propose a dividend of E2.20 per share to the AGM on 26 April 2024. This is in line with the previous year's dividend.

We recorded solid results in the transition year 2023, despite difficult market conditions, demonstrating the strength of our business. Our diversified businesses will continue to benefit from attractive market growth opportunities also in the medium term, management said.

Now we are fully focused on gradually returning to growth in fiscal 2024, while defining our strategic roadmap to ensure long-term profitable and sustainable growth for Merck.

Regarding forecasts for FY 2024, management targets a return to organic growth: sales and EBITDA growth should be slight to moderate.


Copyright (c) 2024 CercleFinance.com. All rights reserved.